Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose Intolerance

You are here:
  1. Home
  2. Corporate News
  3. Rameda Expands Freely Priced Portfolio…
Go to Top